Structure of LINC00511-siRNA-conjugated nanobubbles and improvement of cisplatin sensitivity on triple negative breast cancer

In the present study, we prepared a novel theranostic agent loaded with LINC00511-siRNA, which not only can serve as the siRNA delivery platform but also as the UCA for contrast enhanced ultrasound (CEUS). Combined with low-frequency ultrasound exposure, the novel theranostic agent achieves the controlled release of LINC00511-siRNA and facilitates the transfection of LINC00511-siRNA. Furthermore, in order to investigate how LINC00511 affects drug resistance of TNBC, we conducted the RNA-Seq to gain new insights into the mechanisms of drug sensitivity. Overall design: MDA-MB-231 cells and MDA-MB-231/CDDP cells were used for the research. The cells were transfected using the nanoparticles with the aid of low-frequency ultrasound(LFUS) exposure. Two groups of pre-transfection cells and two groups of post-transfection cells were analyzed using high-throughput RNA sequencing.